DiD

Challenging engrained treatment behaviors: Disrupt the Decline

Despite clinical acceptance of the efficacy of long-acting injectables (LAIs) to provide prolonged stability for people suffering from schizophrenia, they still only make up about 13% of the market. Psychiatrists continue to prescribe daily orals, often citing patient acceptance as a major barrier. This fuels a cycle of oral nonadherence that often leads to relapse and loss. ​

Challenging engrained treatment behaviors: Disrupt the Decline Read More »

Dramatically improving audience quality and campaign ROI with LCI targeting data overlays

CASE STUDY: AUDIENCE TARGETING The Challenge MAVENCLAD positions itself as the Oral of Choice for first switch in Active RMS. The MS market is crowded with many sizable competitors, all fighting for the same patients. MAVENCLAD suffered a series of budget cuts that left the media budget at ~65% of initial OOP contract value ($13M vs $20M), below the spending

Dramatically improving audience quality and campaign ROI with LCI targeting data overlays Read More »

Infusing innovation with emotion to launch a one-of-a-kind product

CASE STUDY: EMOTIONAL STORYTELLING​ The Challenge Branded Narcan was planning for commercial launch of a branded product in a complex generic market, at a time of unprecedented public health awareness and heightened collaborative efforts to solve the growing opioid epidemic in the United States​.​ The brand believed that branded Narcan could be an important part of the broader

Infusing innovation with emotion to launch a one-of-a-kind product Read More »

Get in touch

Looking for a new partner to help grow your brand? Are you looking for advice on healthcare communication challenges? Let’s talk.
*Fields marked with an asterisk are required
Scroll to Top